Oncotype DX Assay May Help Guide Node Positive, ER+ Breast Cancer Treatment

American researchers reported today that the Oncotype DX test can help identify individuals who benefit most from the addition of chemotherapy to tamoxifen treatment for node positive, hormone receptor positive breast cancer, based on a decade long study of post-menopausal patients.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.